Advanced Therapy Medicinal Products Market Outlook 2031
The Advanced Therapy Medicinal Products Market size was USD 10.22 Billion in 2022 and is likely to reach USD 30.70 Blliion by 2031, expanding at a CAGR of 13% during the forecast period, 2023–2031.
The growth of the market is attributed to the success of products including Zolgensma, Kymriah, and others. The disease treatment landscape and pharmaceutical industry have been transformed by the development of Advanced Therapy Medicinal Products (ATMPs). This development has propel the treatment of various cancer types and incurable diseases.
The COVID-19 situation has triggered the advanced application of therapies in virology research to a large extent. Based on study, in December 2020, T- cell therapy has potential to do the treatment on the high-risk COVID-19 patients. Before, in September 2020, ALVR109 designed was approved by the U.S. FDA for the treatment of COVID-19 infected individuals.
For SARS-CoV2 infection it is estimated to increase R&D investment in advanced therapy. Moreover, increasing number of Mesenchymal Stromal/Stem cells (MSCs) based clinical trials is a new treatment pattern for SARS-CoV-2 infection. Even though the ATMPs market currently is in its emerging stage still it is rising significantly. Conventional drug manufacturers are considering advanced therapy medicinal products as a remunerative source of revenue for healthcare systems in future. Presently, this market is very attractive and various market players are suggestively investing in clinical trials of ATMPs after success of approved products.
In recent years, various small molecule and proteins based developing companies are concentrating on the adoptive T cell therapies development. For instance, in March 2021, Bristol Myers Squibb is collaborated with bluebird bio and taken the U.S. FDA approval for Abecma (idecabtagene vicleucel). Abecma is a cell-based gene therapy medicinal product which is developed for treating patients having multiple myeloma.
Advanced Therapy Medicinal Products Market Trends, Drivers, Restraints, and Opportunities
- Advancements in technology of biological therapies are combined with steady shift towards personalized medicine from consumers is anticipated to propel the market growth.
- Increasing product approvals by regulatory bodies, benefits related to the usage of advanced theory, and rising demand of gene therapies are expected to fuel the ATMPs market growth.
- Growing prevalence of Alzheimer’s disease around the world is major factor responsible for the growth of the market during the forecast period.
- Increasing consumer demand, upcoming trend, and industrial development are propelling the growth of the market in coming years.
- Expensive therapies of advanced therapy medicinal products are projected to impede the market growth over the forecast period.
- Lack of funds, stringent regulations, and inadequate transparency are major factors that are estimated to hamper the market growth.
Scope of Advanced Therapy Medicinal Products Market Outlook Report
The report on the global advanced therapy medicinal products market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Advanced Therapy Medicinal Products Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Therapy Types (Car-T Therapy, Gene Therapy, Cell Therapy [Stem Cell Therapy and Non-Stem Cell Therapy], and Tissue Engineered Product)
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report
Spark Therapeutics, Inc., Bluebird Bio, Inc., Novartis AG, UniQure N.V., Celgene Corporation, Gilead Lifesciences, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., MEDIPOST, Vericel Corporation, PHARMICELL Co., Ltd, and Organogenesis Inc.
Advanced Therapy Medicinal Products Market Segment Insights
CAR-T segment is expected to grow at a rapid pace
Based on theory types, the advanced therapy medicinal products market is bifurcated into CAR-T therapy, gene therapy, cell therapy, and tissue engineered product. The cell therapy is further subdivided into stem cell therapy and non-stem cell therapy. The tissue-engineered product segment dominated the market share in 2020 and is expected to hold a key share of the market during the forecast period owing to growing number of publications, increasing clinical trials, research studies, and translational products.
The growth of the segment is attributed to combination of treatment procedures and tissue-engineered procedures or products, mainly for treatments where functional restoration of injured body part is required. Moreover, continuous advancements in products and technology to advance the process helps in the growth of the segment
However, the CAR-T therapy segment is anticipated to expand at a rapid pace during the forecast period. Some key players including Gilead Sciences, Inc., Bristol Myers Squibb, and Novartis AG are intensive for the expansion of their CAR-T products around the world. Due to this investment flow is shifted toward the CAR-T products development, leading to substantial growth of the segment.
North America is anticipated to dominate the market
On the basis of regions, the advanced therapy medicinal products market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to substantial investments in research and development, successful launch of products, and favorable regulatory environment. Moreover, the swiftly growing number of clinical trials in this new treatment modality in the U.S. boosts regional growth.
As of March 2021, in the U.S. around 56.8% of total clinical trials are going on for gene therapy. This major share shows the growing investment flow in advanced therapy medicinal product market thereby boosting the revenue generation.
Europe accounted second-largest market share in 2020 owing to strong research base for advanced therapies. In the cell and gene therapy market China has developed as a potential market for advanced therapies and ranked as second across globe. Intensive efforts, government investment and reforms in China fuels the regional growth.
- Cell Therapy
- Stem Cell Therapy
- Non-stem Cell Therapy
- CAR-T Therapy
- Gene Therapy
- Tissue Engineered Product
- Asia Pacific
- North America
- Latin America
- Middle East & Africa
- Spark Therapeutics, Inc.
- Bluebird Bio, Inc.
- Novartis AG
- UniQure N.V.
- Celgene Corporation
- Gilead Lifesciences, Inc.
- Kolon TissueGene, Inc.
- JCR Pharmaceuticals Co., Ltd.
- Vericel Corporation
- PHARMICELL Co., Ltd.
- Organogenesis Inc.
Key players competing in the advanced therapy medicinal products market include Spark Therapeutics, Inc., Bluebird Bio, Inc., Novartis AG, UniQure N.V., Celgene Corporation, Gilead Lifesciences, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., MEDIPOST, Vericel Corporation, PHARMICELL Co., Ltd, and Organogenesis Inc.
Many key players are focusing on business strategies such as mergers, acquisitions, partnerships, collaborations, capacity expansion, and product launches to increase/enhance their market shares. For instance, Kite Pharma was acquired by Gilead Life Science, Novartis acquired AveXis, and Juno Therapeutics was acquired by Celgene. These acquisitions show the rising interest of well-established pharmaceutical companies in the market.